Lead programme: Flavivirus for Dengue Fever
Our most advanced development programme is a Flavivirus vaccine candidate primarily against Dengue Fever (DV1-DV4), which may also deliver responses against other Flaviviruses such as the Zika and Yellow Fever viruses.
This programme has successfully completed preclinical testing. Phase I and subsequent clinical trials are planned to start in Switzerland, Singapore and Brazil.